Abstract
Drug-induced liver injury (DILI) is a leading cause of liver failure and an important safety issue in drug development. Thalidomide is nowadays used for the treatment of several conditions including multiple myeloma (MM). Several adverse effects have been described but liver toxicity was seldom reported. We describe a case of thalidomide-induced hepatitis in a man treated for MM. The clinical setting and temporal association between the start of the drug and liver injury allowed the assumption of the causative role of thalidomide. As its clinical indications expand we wish to increase awareness of a new potential side effect of thalidomide. A short review on thalidomide-induced liver injury is also presented.
Copyright © 2012 Elsevier España, S.L. and AEEH y AEG. All rights reserved.
MeSH terms
-
Acute Disease
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biopsy
-
Chemical and Drug Induced Liver Injury / etiology*
-
Chemical and Drug Induced Liver Injury / pathology
-
Darbepoetin alfa
-
Diazepam / therapeutic use
-
Erythropoietin / analogs & derivatives
-
Erythropoietin / therapeutic use
-
Fatal Outcome
-
Humans
-
Jaundice, Obstructive / chemically induced*
-
Jaundice, Obstructive / pathology
-
Liver Function Tests
-
Male
-
Melphalan / administration & dosage
-
Multiple Myeloma / complications
-
Multiple Myeloma / drug therapy
-
Omeprazole / therapeutic use
-
Pneumonia / complications
-
Polypharmacy
-
Prednisolone / administration & dosage
-
Thalidomide / administration & dosage
-
Thalidomide / adverse effects*
Substances
-
Erythropoietin
-
Darbepoetin alfa
-
Thalidomide
-
Prednisolone
-
Omeprazole
-
Diazepam
-
Melphalan